GSK Triumphs In Avodart Patent Challenge

Law360, Washington (August 12, 2013, 7:33 PM EDT) -- GlaxoSmithKline LLC scored a win Friday when a Delaware federal judge upheld its patent for the prostate reduction pill Avodart, saying Banner Pharmacaps Inc., Mylan Pharmaceuticals Inc. and other generic-drug makers hadn't shown that the patent was invalid.

U.S. District Judge Richard G. Andrews said Banner, Mylan, Roxane Laboratories Inc., Watson Laboratories Inc. and Impax Laboratories Inc. failed to provide clear and convincing evidence that any asserted claim of GSK's patent-in-suit was invalid during a January bench trial. The patent-in-suit, U.S. Patent Number 5,565,467, covers dutasteride,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.